Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression

American Journal of Clinical Pathology

Volumn 139, Issue 5, 2013, Pages 587-598

  Takeda, Masahiko ^a,b   Mikami, Tetuo ^b   Numata, Yoshiko ^b   Okamoto, Makito ^a   Okayasu, Isao ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BFGF; BMP 2; Heterotopic ossification; Myofibroblast; Nodular fibrosis; Papillary thyroid carcinoma; VEGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN 2; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; NESTIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; FIBROSIS; HETEROTOPIC OSSIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUMORAL HETEROTOPIC OSSIFICATION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE CANCER; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; THYROID CARCINOMA; TUMOR INVASION;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; BONE MORPHOGENETIC PROTEIN 2; CAPILLARIES; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTOR 2; FIBROSIS; HUMANS; INTERMEDIATE FILAMENT PROTEINS; LYMPH NODES; LYMPHATIC METASTASIS; MICROCIRCULATION; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOVASCULARIZATION, PATHOLOGIC; NERVE TISSUE PROTEINS; OSSIFICATION, HETEROTOPIC; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878056510     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQZQN50HKIAHA     Document Type: Article

References (38)

1. Lu Z, Mu Y, Zhu H, et al. Clinical value of using ultrasound to assess calcification patterns in thyroid nodules. World J Surg. 2011;35:122-127.
2. Bai Y, Zhou G, Nakamura M, et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol. 2009:22:887-894.
3. Worthley DL, Giraud AS, Wang TC. Stromal fibroblasts in digestive cancer. Cancer Microenviron. 2010;3:117-125.
4. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429-447.
5. Inoue Y, King TE, Jr., Barker E, et al. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002;166:765-773.
6. Dailey L, Ambrosetti D, Mansukhani A, et al. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005;16:233-247.
7. Ribatti D, Vacca A, Rusnati M, et al. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev. 2007;18:327-334.
8. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242:1528-1534.
9. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233-241.
10. Clement JH, Marr N, Meissner A, et al. Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol. 2000;126:271-279.
11. Bieniasz M, Oszajca K, Eusebio M, et al. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009;66:319-326.
12. Hardwick JC, Van Den Brink GR, Bleuming SA, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology. 2004;126:111-121.
13. The Japanese Society of Thyroid Surgery. General Rules for the Description of Thyroid Cancer. 5th ed. Tokyo, Japan: Kanehara; 1996.
14. Williams ED, Doniach I. The post-mortem incidence of focal thyroiditis. J Pathol Bacteriol. 1962;83:255-264.
15. Okayasu I, Fujiwara M, Hara Y, et al. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. Cancer. 1995;76:2312-2318.
16. Sinicrope FA, Ruan SB, Cleary KR, et al. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237-241.
17. Teranishi N, Naito Z, Ishiwata T, et al. Identification of neovasculature using nestin in colorectal cancer. Int J Oncol. 2007;30:593-603.
18. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics of tumours of endocrine organs. In: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004.
19. Yamashita H, Noguchi S, Murakami N, et al. DNA ploidy and stromal bone formation as prognostic indicators of thyroid papillary carcinoma in aged patients: a retrospective study. Acta Pathol Jpn. 1993;43:22-27.
20. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-nodemetastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-3562.
21. Hotomi M, Sugitani I, Toda K, et al. A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis. World J Surg. 2012;36:1231-1240.
22. Verburg FA, Mader U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98:172-180.
23. De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123:2229-2238.
24. Trojan L, Thomas D, Knoll T, et al. Expression of pro-Angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res. 2004;32:97-103.
25. Surowiak P, Murawa D, Materna V, et al. Occurrence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 2007;27:2917-2924.
26. Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082-2090.
27. Kellermann MG, Sobral LM, da Silva SD, et al. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology. 2007;51:849-853.
28. Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008;14:6014-6022.
29. Faridi A, Rudlowski C, Biesterfeld S, et al. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 2002;198:1-5.
30. Elagoz S, Egilmez R, Koyuncu A, et al. The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. Pathol Oncol Res. 2006;12:21-27.
31. de la Torre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer. 2006;13:931-944.
32. Kuribayashi H, Tsuta K, Mizutani E, et al. Clinicopathological analysis of primary lung carcinoma with heterotopic ossification. Lung Cancer. 2009;64:160-165.
33. Hall FT, Freeman JL, Asa SL, et al. Intratumoral lymphatics and lymph node metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:716-719.
34. Yu XM, Lo CY, Chan WF, et al. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11:8063-8069.
35. Yasuoka H, Nakamura Y, Zuo H, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2005;18:1127-1133.
36. Ozdemir D, Ersoy R, Cuhaci N, et al. Classical and follicular variant papillary thyroid carcinoma: comparison of clinical, ultrasonographical, cytological, and histological features in 444 patients. Endocr Pathol. 2001;22:58-65.
37. Ceresini G, Corcione L, Michiara M, et al. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of northern Italy, 1998 to 2009. Cancer. 2012;118:5473-5480.
38. Zhu X, Sun T, Lu H, et al. Diagnostic significance of CK19, PET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010;63:786-789.